Drugs / Rodatristat Ethyl
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT05933447 | May → Jul 2023 | — | Altavant Sciences GmbH | Completed | No outcome recorded |
| Phase 1 | NCT05684640 | Sep 2022 → Jan 2023 | — | Altavant Sciences GmbH | Completed | No outcome recorded |
| Phase 1 | NCT05065359 | Oct 2021 → Mar 2022 | — | Altavant Sciences GmbH | Completed | No outcome recorded |
| Phase 1 | NCT05006118 | Sep → Oct 2021 | — | Altavant Sciences GmbH | Completed | No outcome recorded |
| Phase 1 | NCT02746237 | Nov 2015 → May 2016 | pulmonary arterial hypertension | Karos Pharmaceuticals | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT04712669 | Mar 2021 → Jun 2023 | pulmonary arterial hypertension | Altavant Sciences GmbH | Completed | Missed primary |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rodatristat ethyl | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05006118 ↗ |
| Known as | KAR5585 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02746237 ↗ |
| Action | Inhibit | “Rodatristat Ethyl is a peripherally restricted TPH inhibitor” NCT04712669 ↗1“Tryptophan 5-hydroxylase 1 inhibitor” CHEMBL4069704 ↗ |
| Modality | Small molecule | — CHEMBL4069704 ↗ |
| Route | Oral | “single oral dose” NCT05006118 ↗ |
| Target | TPH1 | “Tryptophan 5-hydroxylase 1 inhibitor” CHEMBL4069704 ↗ |